CRY CryoLife Inc

Company posts third quarter net income of $1.9 million and $0.07 per share compared to $2.0 million and $0.07 per share in 2006; Non-GAAP EPS for third quarter was $0.09 compared to $0.00 per share in 2006 ATLANTA, Nov. 1 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE:CRY), a biomaterials, medical device and tissue processing company, announced today that revenues for the third quarter of 2007 increased 11 percent to $22.2 million compared to $20.0 million in the third quarter of 2006. Net income in the third quarter of 2007 was $1.9 million and $0.07 per basic and fully diluted common share, compared to net income of $2.0 million and $0.07 per basic and fully diluted common share in the third quarter of 2006. Excluding a $601,000 charge related to stock-based compensation, non-GAAP net income in the third quarter of 2007 was $2.5 million and $0.09 per basic and fully diluted common share. Excluding a net $2.0 million gain related to the settlement of an insurance dispute, and a $185,000 charge related to stock-based compensation, non-GAAP net income in the third quarter of 2006 was $170,000 and $0.00 per basic and fully diluted common share. Revenues for the first nine months of 2007 increased 16 percent to $69.7 million compared to $60.2 million in the first nine months of 2006. Net income in the first nine months of 2007 was $4.6 million and $0.17 per basic and $0.16 per fully diluted common share, compared to net income of $415,000 and a net loss of ($0.01) per basic and fully diluted common share in the first nine months of 2006. Excluding a $1.5 million charge related to stock-based compensation, an $821,000 charge for the change in the valuation of the derivative related to the Company's preferred stock, and a $786,000 charge related to post employment benefits, non-GAAP net income in the first nine months of 2007 was $7.7 million and $0.29 per basic and $0.28 per fully diluted common share. Excluding a net $2.0 million gain related to the settlement of an insurance dispute, an $832,000 charge related to stock-based compensation, and a $448,000 charge related to post employment benefits, non-GAAP net loss in the first nine months of 2006 was ($298,000) and ($0.04) per basic and fully diluted common share. "Excluding orthopaedic tissue processing revenues of $566,000 in 2007 and $1.7 million in 2006, non-GAAP revenues for the third quarter of 2007 increased 18 percent compared to 2006," stated Steven G. Anderson, president and CEO of CryoLife, Inc. "The increase in non-GAAP earnings in the third quarter reflects our continued growth in our core cardiac and vascular tissue processing business, as well as our ability to expand gross margins while keeping general and administrative expenses relatively flat on an adjusted basis." Tissue processing revenues in the third quarter of 2007 increased 10 percent to $11.3 million compared to $10.3 million in the third quarter of 2006. Tissue processing revenues in the first nine months of 2007 increased 21 percent to $36.0 million compared to $29.8 million in the first nine months of 2006. Tissue processing revenues increased primarily due to an increase in demand for the Company's cardiac and vascular processed tissues and increased availability of these tissues due to improvements in procurement. Combined cardiac and vascular tissue processing revenues in the third quarter of 2007 increased 25 percent to $10.8 million compared to $8.7 million in the third quarter of 2006. Combined cardiac and vascular tissue processing revenues in the first nine months of 2007 increased 31 percent to $32.4 million compared to $24.6 million in the first nine months of 2006. Combined cardiac and vascular tissue processing revenues increased primarily due to an increase in demand for the Company's processed tissues and increased availability of tissues due to improvements in procurement. Orthopaedic tissue processing revenues in the third quarter of 2007 decreased 66 percent to $566,000 compared to $1.7 million in the third quarter of 2006. Orthopaedic tissue processing revenues in the first nine months of 2007 decreased 30 percent to $3.7 million compared to $5.2 million in the first nine months of 2006. Orthopaedic tissue processing revenues declined during 2007 because the Company discontinued procuring and processing such tissues in the first quarter of 2007. BioGlue(R) revenues were $10.3 million for the third quarter of 2007 compared to $9.4 million in the third quarter of 2006, an increase of 9 percent. U.S. BioGlue revenues were $7.4 million and $7.1 million in the third quarter of 2007 and 2006, respectively. International BioGlue revenues were $2.9 million and $2.3 million in the third quarter of 2007 and 2006, respectively. BioGlue revenues were $32.4 million for the first nine months of 2007 compared to $29.5 million in the first nine months of 2006, an increase of 10 percent. U.S. BioGlue revenues were $23.4 million and $22.0 million in the first nine months of 2007 and 2006, respectively. International BioGlue revenues were $9.0 million and $7.5 million in the first nine months of 2007 and 2006, respectively. Total product and tissue processing gross margins were 63 percent in the third quarter of 2007 compared to 57 percent in the third quarter of 2006. Total product and tissue processing gross margins were 61 percent in the first nine months of 2007 compared to 56 percent in the first nine months of 2006. Tissue processing gross margins in the third quarter of 2007 were 42 percent compared to 33 percent in the third quarter of 2006. Tissue processing gross margins in the first nine months of 2007 were 41 percent compared to 30 percent in the first nine months of 2006. The increase in total product and tissue processing gross margins was primarily the result of price increases. General, administrative, and marketing expenses in the third quarter of 2007 were $11.2 million compared to $8.5 million in the third quarter of 2006. Excluding a $601,000 charge related to stock-based compensation, non-GAAP general, administrative, and marketing expenses in the third quarter of 2007 were $10.6 million. Excluding a net $2.0 million gain related to the settlement of an insurance dispute, and a $185,000 charge related to stock- based compensation, non-GAAP general, administrative, and marketing expenses in the third quarter of 2006 were $10.4 million. General, administrative, and marketing expenses in the first nine months of 2007 were $34.4 million compared to $30.1 million in the first nine months of 2006. Excluding a $1.5 million charge related to stock-based compensation, and a $786,000 charge related to post employment benefits, non-GAAP general, administrative, and marketing expenses in the first nine months of 2007 were $32.1 million. Excluding a net $2.0 million gain related to the settlement of an insurance dispute, an $832,000 charge related to stock-based compensation, and a $448,000 charge related to post employment benefits, non-GAAP general, administrative, and marketing expenses in the first nine months of 2006 were $30.8 million. Research and development expenses were $1.1 million and $826,000 in the third quarters of 2007 and 2006, respectively. Research and development expenses were $3.1 million and $2.6 million in the first nine months of 2007 and 2006, respectively. As of September 30, 2007, the Company had $14.2 million in cash, cash equivalents and marketable securities (at market), of which $1.5 million was received from the U.S. Department of Defense as advance funding for the development of protein hydrogel technology for use on the battlefield. Financial Guidance The Company now expects product and tissue processing revenues for the full year of 2007 to be near or slightly below the lower end of its previously announced range of revenue guidance, which is $93.0 million. The Company expects general, administrative, and marketing expenses of between $45.5 million and $47.0 million, and research and development expenses of between $4.0 million and $5.0 million for the full year of 2007. The Company expects product and tissue processing revenues for the full year of 2008 to be between $100.0 million and $104.0 million. The Company expects BioGlue revenues to be between $47.0 million and $49.0 million, and tissue processing revenues to be between $52.0 million and $54.0 million for the full year of 2008. Other implantable medical device revenues are expected to be approximately $1.0 million in 2008. The Company expects general, administrative, and marketing expenses of between $48.0 million and $51.0 million, and research and development expenses of between $6.0 million and $8.0 million for the full year of 2008. The research and development expectations include an estimate of up to $1.6 million to be funded by the U.S. Department of Defense in connection with the development of BioFoam. Webcast and Conference Call Information The Company will hold a teleconference call and live webcast today at 10:00 a.m. Eastern Time to discuss the results followed by a question and answer session hosted by Mr. Anderson. To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 10:00 a.m. A replay of the teleconference will be available November 1 - November 8, 2007 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The account number for the replay is 244, and the conference number is 257727. The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife Web site at http://www.cryolife.com/ and selecting the heading Webcasts & Presentations. About CryoLife, Inc. Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve which is CE marked for distribution within the European Community. Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding anticipated 2007 and 2008 revenues, general and administrative expenses, and research and development expenses. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. These risks and uncertainties include that the Company's strategic directives may not generate anticipated revenue and earnings growth, the Company's efforts to continue to increase revenue may not be effective, since their effectiveness is subject to such factors as competitive pressures and tissue availability, that the Company's efforts to develop and introduce new products outside the U.S. may be unsuccessful, that the Company's efforts to improve procurement and tissue processing yields may not continue to prove effective, the possibility that the FDA could impose additional restrictions on the Company's operations, require a recall, or prevent the Company from processing and distributing tissues or manufacturing and distributing other products, that products and services under development, including BioDisc, may not be commercially feasible, that the Company's SynerGraft products may not receive FDA approval when anticipated or at all, that the Company may not have sufficient borrowing or other capital availability to fund its business, that pending or future litigation cannot be settled on terms acceptable to the Company, that the Company may not have sufficient resources to pay punitive damages (which are not covered by insurance) or other liabilities in excess of available insurance, and that the Company may be unable to obtain sufficient financing to fully pursue its strategic plan. These risks and uncertainties include the risk factors detailed in CryoLife's Securities and Exchange Commission filings, including CryoLife's Form 10-K filing for the year ended December 31, 2006, its most recent Form 10-Q, and the Company's other SEC filings. The Company does not undertake to update its forward-looking statements. CRYOLIFE, INC. AND SUBSIDIARIES Financial Highlights (In thousands, except per share data) Three Months Ended Nine Months Ended September 30, September 30, 2007 2006 2007 2006 (Unaudited) (Unaudited) Revenues: Preservation services $11,347 $10,319 $36,019 $29,839 Products 10,545 9,687 33,096 30,308 Other 268 12 580 74 Total revenues 22,160 20,018 69,695 60,221 Costs and expenses: Preservation services 6,575 6,954 21,183 20,751 Products 1,615 1,576 5,444 5,581 General, administrative, and marketing 11,240 8,549 34,417 30,106 Research and development 1,098 826 3,134 2,572 Interest expense 178 169 518 504 Interest income (158) (94) (360) (304) Change in valuation of derivative - 44 821 111 Other (income) expense, net (350) 4 (248) 348 Total costs and expenses 20,198 18,028 64,909 59,669 Earnings before income taxes 1,962 1,990 4,786 552 Income tax expense 55 12 234 137 Net income $1,907 $1,978 $4,552 $415 Effect of preferred stock dividends - (243) (243) (730) Net income (loss) applicable to common shares $1,907 $1,735 $4,309 $(315) Income (loss) per common share: Basic $0.07 $0.07 $0.17 $(0.01) Diluted $0.07 $0.07 $0.16 $(0.01) Weighted average common shares outstanding: Basic 27,501 24,847 25,998 24,804 Diluted 28,056 25,118 26,673 24,804 Revenues from: Cardiovascular tissue $5,566 $4,189 $15,587 $11,550 Vascular tissue 5,215 4,468 16,782 13,066 Orthopaedic tissue 566 1,662 3,650 5,223 Total preservation services 11,347 10,319 36,019 29,839 BioGlue 10,280 9,444 32,373 29,534 Other implantable medical devices 265 243 723 774 Total products 10,545 9,687 33,096 30,308 Other 268 12 580 74 Total revenues $22,160 $20,018 $69,695 $60,221 Domestic revenues $18,847 $17,297 $59,659 $51,497 International revenues 3,313 2,721 10,036 8,724 Total revenues $22,160 $20,018 $69,695 $60,221 CRYOLIFE, INC. AND SUBSIDIARIES Financial Highlights (In thousands) September 30, December 31, 2007 2006 (Unaudited) Cash and cash equivalents, marketable securities, at market, and restricted securities $ 14,168 $ 8,669 Trade receivables, net 12,931 12,553 Other receivables 1,439 1,403 Deferred preservation costs, net 25,267 19,278 Inventories 5,571 5,153 Total assets 90,892 79,865 Shareholders' equity 59,256 52,088 CRYOLIFE, INC. AND SUBSIDIARIES Unaudited Reconciliation of Non-GAAP Net Income (Loss) (In thousands, except per share data) Three Months Ended Nine Months Ended September 30, September 30, 2007 2006 2007 2006 Net income - as reported $ 1,907 $ 1,978 $ 4,552 $ 415 Adjustments to net income: Insurance settlement - (1,993) - (1,993) Stock-based compensation 601 185 1,524 832 Post employment benefits - - 786 448 Change in valuation of derivative - - 821 - Non-GAAP net income (loss) $ 2,508 $ 170 $ 7,683 $ (298) Effect of preferred stock dividends - (243) (243) (730) Non-GAAP net income (loss) applicable to common shares $ 2,508 $ (73) $ 7,440 $ (1,028) Weighted average common shares outstanding - Basic 27,501 24,847 25,998 24,804 Non-GAAP income (loss) per common share - Basic $ 0.09 $ (0.00) $ 0.29 $ (0.04) Numerator for non-GAAP diluted income (loss) per common share: Non-GAAP net income (loss) $ 2,508 170 $ 7,683 (298) Less effect of preferred stock dividends - (243) (243) (730) Non-GAAP net income (loss) applicable to common stock $ 2,508 (73) $ 7,440 (1,028) Denominator for non-GAAP diluted income (loss) per common share: Basic weighted-average common shares 27,501 24,847 25,998 24,804 Effect of dilutive stock options 555 - 675 - Weighted average common shares outstanding - Diluted 28,056 24,847 26,673 24,804 Non-GAAP income (loss) per common share - Diluted $ 0.09 $ (0.00) $ 0.28 $ (0.04) CRYOLIFE, INC. Unaudited Reconciliation of Non-GAAP General, Administrative, and Marketing Expenses (In thousands) Three Months Ended Nine Months Ended September 30, September 30, 2007 2006 2007 2006 General, administrative, and marketing expense - as reported $ 11,240 $ 8,549 $ 34,417 $ 30,106 Adjustments to G&A expense: Insurance settlement - 1,993 - 1,993 Stock-based compensation (601) (185) (1,524) (832) Post employment benefits - - (786) (448) Non-GAAP general, administrative, and marketing expense $ 10,639 $ 10,357 $ 32,107 $ 30,819 For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com/ Media Contacts: D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating Officer Phone: 770-419-3355 Katie Brazel Fleishman Hillard Phone: 404-739-0150 DATASOURCE: CryoLife, Inc. CONTACT: D. Ashley Lee, Executive Vice President, Chief Financial Officer and Chief Operating Officer of CryoLife, Inc., +1-770-419-3355; or Katie Brazel of Fleishman Hillard, +1-404-739-0150 Web site: http://www.cryolife.com/

Copyright